How do pharma and biotech companies build a CMC strategy that accelerates marketing authorisation rather than slowing it down?
We support the entire CMC lifecycle: CMC strategy, CTD Module 3, agency communication and post-approval variations, aligned with ICH Q8, Q9 and Q10. Formulation, process and supplier selection are regulatory decisions: treating them as such early avoids the costly changes in a running program.
Overview
Which CMC challenges arise during the authorization process?
Support across the entire CMC lifecycle · CTD Module 3, ICH Q8, Q9, Q10
Last updated: June 13, 2026
Chemistry, Manufacturing and Controls (CMC) covers the pharmaceutical and technical aspects of a medicinal product: characterization of the active substance and finished product, manufacturing process, quality control, specifications and stability. These data form CTD Module 3 of the marketing authorisation dossiers.
- Incomplete or poorly structured CMC documentation in CTD Module 3 triggers questions from the agency and delays the assessment.
- Changes to formulation, manufacturing process, specifications or suppliers after authorization require variations under the Variations Regulation (EC) No 1234/2008 and must be planned rather than handled reactively.
- Scale-up from laboratory to production scale without regulatory support creates compliance risks, because the validated process differs from the one submitted.
- CMC requirements of EMA and FDA as well as the ICH guidelines Q8 to Q10 must be met in parallel, as expectations regarding data depth and justification diverge.
Services
How we support you
CMC Strategy & Development Support
Development of a regulatorily robust CMC strategy for new active substance formulations, integration of CMC milestones into the clinical development plan and early agency communication on CMC matters. Deliverable: documented CMC strategy with a milestone plan.
CMC Variations & Lifecycle Management
Management of post-approval variations (manufacturer changes, process optimizations, new manufacturing sites as well as changes to formulation and specifications) and coordination between Regulatory Affairs and the manufacturing sites. Deliverable: variation classification and submitted variation documentation.
How we work together
What it comes down to
What holds an authorization up in Chemistry, Manufacturing and Controls is rarely a missing data requirement. Three decisions carry across the entire lifecycle: the formulation, the manufacturing process and the supplier selection. They all end up in CTD Module 3 and must be scientifically justified against the Quality by Design logic of ICH Q8, Q9 and Q10.
Companies that make these determinations only after the clinical phase has begun turn them into a bottleneck, because in the worst case every later change brings new stability data, a renewed process validation and a variation in its wake.
The CMC strategy identifies early on which determination is critical, before the dossier is written and the process is validated at commercial scale. Changes are still inexpensive at that point. The same bottleneck becomes visible during tech transfer: if the validated production process deviates from the submitted development process, a gap opens up between the dossier and reality.
After authorization, every correction then becomes a variation under (EC) No 1234/2008, which usually runs as an approval-requiring Type II change rather than a simple internal adjustment.
Our approach
Our approach
Step
Result
CMC Assessment & Strategy
Assessed CMC status, documented strategy and CMC milestones anchored in the clinical development plan.
CTD Module 3 Build
Structured CTD Module 3 covering active substance, finished product and stability, reconciled against ICH Q8-Q10.
Review & Gap Closure
Reviewed Module 3 with a prioritized gap list and critical gaps closed before submission.
Agency Communication
Prepared and supported CMC communication with EMA or FDA, with documented responses to questions.
Tech Transfer & Scale-up
Supported transfer to commercial scale with a validation plan and assessment of the regulatory consequences.
Lifecycle & Variations
Classified and submitted variations under (EC) No 1234/2008, coordinated between RA and manufacturing.
Common pitfalls
Where projects commonly fail
CMC planning starts too late.
Decisions on formulation, process and excipients have long-term regulatory consequences; if they are made only after the clinical phase has begun, later changes are costly and can delay the clinical program.
CTD Module 3 is incomplete or poorly structured.
A missing link between specifications, methods and stability data triggers agency questions that pull the procedure into loops instead of leading it straight to authorization.
Scale-up is carried out without regulatory support.
If the validated production process deviates from the submitted development process, a gap opens up between the dossier and reality that surfaces at the latest during inspection or review.
Post-approval changes are not planned as variations.
Manufacturer changes or process adjustments without correct classification under (EC) No 1234/2008, for example as an approval-requiring Type II variation, risk being implemented without a valid regulatory basis.
EMA and FDA requirements are treated as identical.
Writing a single CMC package for both regions without accounting for the differing expectations on data depth and justification produces regional requests for further information.
Product Development & Regulatory Strategy
Do any of these pitfalls apply to you?
In a first call we assess your situation and say what needs clarifying first in your case. Without obligation, reply usually within one working day.
FAQ
Frequently asked questions
Sources
- ICH Q8 (R2) Pharmaceutical Development, ICH Q9 Quality Risk Management, ICH Q10 Pharmaceutical Quality System (primary texts)
- Regulation (EC) No 1234/2008 on the examination of variations to marketing authorisations (Variations Regulation, primary text)
- Common Technical Document (CTD), Module 3 Quality (structure)
- Writer material: Entourage Website Writer, expertise-pages/clinical-medical-affairs/cmc-strategie
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Projects from this industry
What we have worked on in this industry
Related insights
All insights →Regulations & standards considered
- ICH Q8 (Pharmaceutical Development)
- ICH Q9 (Quality Risk Management)
- ICH Q10 (Pharmaceutical Quality System)
- CTD Module 3 (Quality / Common Technical Document)
- Regulation (EC) No 1234/2008 (Variations Regulation)
Related topics
GMP Consulting (Good Manufacturing Practice) →
Manufacturing compliance that substantiates the CMC dossier in production
Regulatory Affairs →
Authorization strategy and agency management beyond CMC
Production Transfer & Scale-Up →
Tech transfer and scale-up with regulatory support
Technical Writing →
Structured authoring of the CTD documentation
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +39 02 8904 1000
info@theentourage.it
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences